ArticleTranslational andrology and urology2025
Nomogram for predicting acute kidney disease in patients with upper tract urothelial carcinoma undergoing adjuvant chemotherapy following radical nephroureterectomy.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erratum: Nomogram for predicting acute kidney disease in patients with upper tract urothelial carcinoma undergoing adjuvant chemotherapy following radical nephroureterectomy.Translational andrology and urology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radical nephroureterectomy (RNU) with complete bladder cuff excision is the primary treatment for high-risk non-metastatic upper urinary tract urothelial carcinoma (UTUC). Gemcitabine-platinum combination chemotherapy is established as the preferred adjuvant therapy post-RNU; however, both RNU and platinum-based therapies can significantly impair renal function. This study aimed to construct a nomogram to predict acute kidney disease (AKD) occurrence in UTUC patients undergoing gemcitabine-platinum chemotherapy after RNU. Methods: We collected data from patients who underwent RNU followed by adjuvant gemcitabine-platinum chemotherapy at Beijing Friendship Hospital, Capital Medical University, between September 2015 and September 2024. Demographic, perioperative, and pre-chemotherapy data were analyzed. After rigorous screening, 126 patients were included and randomly allocated to a development cohort (n=88, 70%) and a validation cohort (n=38, 30%) in a 7:3 ratio. Risk factors for AKD identified by univariate and backward stepwise multivariate logistic regression analyses were used to develop the nomogram. Its performance was assessed using calibration curves, Harrell's concordance index (C-index), decision curve analysis (DCA), and clinical impact curve (CIC) analysis. Results: AKD occurred in 31 patients (24.6%). Multivariate logistic regression identified five significant independent predictors: age (P=0.04), diabetes mellitus (P=0.03), proteinuria (P=0.003), serum creatinine before chemotherapy (P=0.002), and postoperative acute kidney injury (AKI) (P=0.01). The nomogram demonstrated strong discriminatory power, with an area under the curve (AUC) of 0.895 [95% confidence interval (CI): 0.825-0.964] in the development cohort and 0.893 (95% CI: 0.776-1.000) in the validation cohort. DCA and CIC indicated good clinical utility. Conclusions: Age, diabetes mellitus, preoperative proteinuria, serum creatinine before chemotherapy, and postoperative AKI are significant risk factors for AKD in UTUC patients receiving gemcitabine-platinum chemotherapy after RNU. The developed nomogram serves as an effective predictive tool for AKD in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.